New immunotherapy trial for Type 1 diabetes

March 25, 2016
New immunotherapy trial for Type 1 diabetes

The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy's Hospital in London.

The new immunotherapy treatment, called MultiPepT1De, is being developed to target the autoimmune attack that leads to the development of Type 1 .

Type 1 diabetes is an autoimmune disease in which cells in the pancreas that make insulin are killed by the immune system. The new therapy, MultiPepT1De, will use fragments of proteins, known as peptides, in an effort to stop this process by 'switching off' the specific , and hopefully preventing further destruction of the pancreatic cells.

In laboratory testing, MultiPepT1De is more powerful than the first generation treatment trialled last year and is designed to benefit a higher proportion of those with Type 1 diabetes than its predecessor.

MultiPepT1De was developed with funding from the Wellcome Trust by researchers at King's College London working in the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy's and St Thomas' and King's College London.

MultiPepT1De will be trialled on 24 people with Type 1 diabetes by autumn 2016 and the study team is hopeful of positive results that build upon their previous findings showing that the first generation of MultiPepT1De, called MonoPepT1De, is safe and well tolerated, with some evidence of positive effects in T1D patients.

Professor Mark Peakman, Principal Investigator at the BRC and Head of the Division of Diabetes and Nutritional Sciences at King's, said: "We are really looking forward to seeing the results from this new trial. What we are doing is a big step forward in precision medicine, taking a set of patients with a particular disease and genetic background and giving them an immunotherapy designed in the laboratory specifically for them. Obviously we will need to wait until we have the full results of the trial before we know if it is successful but at this stage we are hopeful."

Dr Stephen Caddick, Director of Innovations at the Wellcome Trust, said: "Type 1 diabetes is a very serious condition that normally requires lifelong treatment with insulin therapy, but this promising new form of 'immunotherapy' could be set to change that. By retraining the immune system to prevent it from attacking insulin-producing cells, it may be possible to slow progression of the disease or even stop it in its tracks. If this approach is proved successful in larger studies it has the potential to transform the lives of people with Type 1 diabetes."

In the last decade, the number of people in the UK with diabetes has risen by around 65 per cent to 4m, according to Diabetes UK, with around 400,000 adults and children now suffering from Type 1 diabetes. Treating diabetes is estimated to cost the NHS around £10 billion per year.

MultiPepT1De is based on an area of study called peptide immunotherapy, which is currently being applied to a number of other diseases, including allergies and multiple sclerosis.

Jeremy Hunt, Secretary of State for Health, said: "This exciting new treatment has the potential to transform the lives of thousands of patients across the UK living with Type 1 diabetes. Thanks to our strong economy we invest over £1 billion every year in health research, helping us to lead the world in medical innovation and give NHS patients the latest cutting-edge treatments."

Explore further: Work starts on new therapy to prevent Type 1 diabetes

Related Stories

Work starts on new therapy to prevent Type 1 diabetes

April 27, 2012
Scientists at King’s College London have launched a project to develop a new therapy for Type 1 diabetes.  It is hoped the therapy will control the autoimmune responses that underlie the inflammation that leads ...

A pharmacological approach to improving pancreatic beta cell growth and function

March 17, 2016
β cells in pancreatic islets are responsible for producing insulin, which is essential to regulate blood glucose homeostasis. In type 1 diabetes, pancreatic β cells are destroyed due to an autoimmune attack, whereas in ...

Scientists identify factor that may trigger type 1 diabetes

February 11, 2016
A team of researchers, led by investigators at the University of Colorado School of Medicine, have identified a new class of antigens that may be a contributing factor to type 1 diabetes, according to an article published ...

The next step in preventing diabetes

March 15, 2016
A team of scientists at Helmholtz Zentrum München, in collaboration with Technische Universität München and the German Center for Diabetes Research (DZD), have shown in a preclinical model that specifically modified insulin ...

Innovative trial aims to induce remission of type 2 diabetes

December 15, 2015
Remission is well-known as the goal in cancer treatment but scientists are discovering it's also an exciting possibility for those with type 2 diabetes.

Could a bacteria-killing protein lead to a new treatment for diabetes?

February 24, 2016
Why would a bacteria-killing protein be present in an area of the body that is not normally exposed to bacteria, like the pancreas? Researchers at The Ottawa Hospital and the University of Ottawa puzzled over this question ...

Recommended for you

People who drink 3 to 4 times per week less likely to develop diabetes than those who never drink: study

July 27, 2017
Frequent alcohol consumption is associated with a reduced risk of diabetes in both men and women, according to a new study published in Diabetologia (the journal of the European Association for the Study of Diabetes), with ...

Diabetes can be tracked with our Google searches

July 26, 2017
The emergence of Type 2 Diabetes could be more effectively monitored using our Google searches—helping public health officials keep track of the disease and halt its spread—according to research by the University of Warwick.

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.